Atyr PHARMA’s (ATYR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report report published on Tuesday, Benzinga reports. HC Wainwright currently has a $35.00 price target on the stock.

A number of other analysts have also issued reports on ATYR. Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 price target on shares of Atyr PHARMA in a research note on Wednesday, August 14th. Wells Fargo & Company began coverage on shares of Atyr PHARMA in a research note on Friday, October 4th. They set an “overweight” rating and a $17.00 target price on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Atyr PHARMA in a research report on Thursday, September 5th. They issued a “buy” rating and a $9.00 price target for the company.

Atyr PHARMA Stock Performance

Shares of ATYR stock opened at $3.32 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.63 and a current ratio of 7.63. The firm has a market cap of $229.12 million, a price-to-earnings ratio of -3.69 and a beta of 1.21. The business has a 50 day moving average of $2.14. Atyr PHARMA has a one year low of $1.08 and a one year high of $3.68.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. As a group, research analysts predict that Atyr PHARMA will post -0.91 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.